Hanmi Pharm (KRX:128940) secured a supply agreement for three cardiovascular and respiratory products from New Jersey-based Organon International, according to a Thursday filing with the Korea Exchange.
The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.
Shares of Hanmi Pharm added more than 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments